Although predictive biomarkers such as PD-L1 immunohistochemistry tumor proportion score (PD-L1 TPS) and tumor mutational burden (TMB) are of value in some patients, each suffers from several limitations that compromise their predictive accuracy and use in clinical practice. Here, CD274 is linked to neoplasm.